New hope for aHUS patients in china: eculizumab shows promise
NCT ID NCT05876351
First seen Jan 03, 2026 · Last updated May 20, 2026 · Updated 22 times
Summary
This study tested a drug called eculizumab in 25 children and adults in China with a rare blood and kidney disease called aHUS. The goal was to see if the drug could improve blood counts and kidney function. Participants received the drug and were monitored for safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATYPICAL HEMOLYTIC UREMIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Beijing, 100034, China
-
Research Site
Beijing, 100045, China
-
Research Site
Changsha, 410007, China
-
Research Site
Qingdao, 110016, China
-
Research Site
Taiyuan, 030012, China
-
Research Site
Wuhan, 430030, China
Conditions
Explore the condition pages connected to this study.